https://www.selleckchem.com/pr....oducts/ttnpb-arotino
tinib or erlotinib could be a higher risk to occur EGFR T790M mutation. NSCLC patients with hOGG1-Cys variants might be helpful to predict patients having higher risk of EGFR exon 19 deletion mutations and these patients who were treated with gefitinib or erlotinib could be a higher risk to occur EGFR T790M mutation.Percutaneous thermal ablation is an important treatment for lung cancer and is widely used in hospitals. Puncture biopsy is generally required for pathological diagnosis before or after thermal ablation. Patholo
Like
Comment
Share
